Skip to main content


Fig. 1 | BMC Medicine

Fig. 1

From: Advances in the treatment of newly diagnosed glioblastoma

Fig. 1

Frequency, overlap, and relative survival of glioblastomas (GBs) (includes GB and all GB variants including gliosarcoma) based on molecular profile. Relative frequency of G-CIMP status, gene expression profiles, IDH1 mutation, and MGMT promoter methylation in GBs. IDH1 mutation and G-CIMP are depicted as discrete categories, while gene expression and MGMT methylation status are depicted as a continuum. GBs with a proneural gene expression profile and IDH1 mutations cluster almost exclusively within G-CIMP GBs, and have improved clinical outcomes (left side). Mesenchymal GBs are exclusively non-G-CIMP and IDH1 wild-type, and have inferior clinical outcomes. G-CIMP, CpG island methylator phenotype; IDH1 mut, isocitrate dehydrogenase 1 gene mutation; IDH1 wt, isocitrate dehydrogenase 1 wild-type gene. Adapted from Theeler BJ et al. [33], with permission from Wolters Kluwer Health, Inc.

Back to article page